secwatch.observer — SEC 8-K summary
======================================

Issuer:     biote Corp. (BTMD)
CIK:        0001819253
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001193125-24-065961
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biote Q4 revenue $45.7M (+2.7% YoY), net income $12.1M; FY adj. EBITDA $55.3M (+10.2%)
--------------------------------------------------------------------------------

- Q4 procedure revenue $34.9M (+6.6%); gross margin 69.4% (up >400 bps); diluted EPS $0.18.
- Full-year revenue $185.4M (+12.4%); net loss $2.8M; adj. diluted EPS $0.13.
- Practitioner network grew to 7,100 from 6,400; launched BioteRx hormone/wellness line.
- Agreed to repurchase 18.4M founders' shares plus separate $20M buyback program.
- Reaffirmed 2024 guidance with expectation of accelerated growth in H2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819253/000119312524065961/0001193125-24-065961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819253/000119312524065961/d759704d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-065961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer